| PIBP incidence | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|
 | N (%) | OR | 95% CI | p-value* | OR | 95% CI | p-value* |
Sex | Â | Â | Â | Â | Â | Â | Â |
 Male | 2 (3) | Reference | Reference | ||||
 Female | 28 (12) | 5.54 | 1.29–23.83 | 0.021 | 1.99 | 0.36–11.0 | 0.413 |
Age | Â | Â | Â | Â | Â | Â | Â |
 <55 years | 21 (20) | 5.31 | 2.32–12.07 | > 0.001 | 3.68 | 1.52–8.90 | 0.003 |
 ≥55 years | 9 (5) | Reference | Reference | ||||
Pre-existing osteoporosis | Â | Â | Â | Â | Â | Â | Â |
 Yes | 0 | NA | - | ||||
 No | 30 (10) | NA | - | ||||
Type of tumor | Â | Â | Â | Â | Â | Â | Â |
 Solid cancers | 27 (14) | 5.39 | 1.60–18.21 | 0.007 | 2.73 | 0.60–12.43 | 0.183 |
 Hematologic cancers | 3 (3) | Reference | Reference | ||||
Bone metastasis | Â | Â | Â | Â | Â | Â | Â |
 Present | 3 (10) | 0.71 | 0.21–4.84 | 0.596 | - | ||
 Absent | 27 (10) | Reference | - | ||||
Opioids | Â | Â | Â | Â | Â | Â | Â |
 Yes | 1 (8) | 0.79 | 0.09–6.02 | 0.784 | - | ||
 No | 29 (10) | Reference | - | ||||
NSAIDs | Â | Â | Â | Â | Â | Â | Â |
 Yes | 2 (13) | 1.33 | 0.28–6.16 | 0.714 | - | ||
 No | 28 (10) | Reference | - | ||||
Prior chemotherapy | Â | Â | Â | Â | Â | Â | Â |
 Yes | 4 (14) | 1.61 | 0.52–4.99 | 0.412 | - | ||
 No | 26 (9) | Reference | - | ||||
Type of chemotherapy | Â | Â | Â | Â | Â | Â | Â |
 Adjuvant chemotherapy | 21 (14) | 2.93 | 1.29–6.62 | 0.010 | 1.14 | 0.40–3.23 | 0.804 |
 Chemotherapy alone | 9 (6) | Reference | Reference | ||||
Type of prophylaxis | Â | Â | Â | ||||
 Primary | 23 (9) | 1.48 | 0.60–3.64 | 0.410 |  |  |  |
 Secondary | 7 (13) | Reference |  | ||||
Pegfilgrastim injection | Â | Â | Â | Â | Â | Â | Â |
 Day 2 or 3 | 10 (8) | Reference | - | ||||
 Days 4–7 | 20 (11) | 1.53 | 0.69–3.38 | 0.298 | - |